Direct oral anticoagulants and warfarin for venous thromboembolism treatment: Trends from 2012 to 2017

摘要

BackgroundDirect oral anticoagulants (DOACs), namely rivaroxaban, apixaban, dabigatran, and edoxaban, are now included together with warfarin as standards of care for the primary treatment of venous thromboembolism (VTE). The extent to which the DOACs have been adopted since receiving US Food and Drug Administration (FDA) approval is unknown.